Skip to main content

Table 1 Patient characteristics and treatment parameters

From: Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Variable

SRS and ipilimumab

SRS and nivolumab

 

N = 45

N = 35

p

Sex (F/M)

17/28

14/21

1.0

Age (years)

 median

54

56

0.2

 range

23–78

26–80

 

KPS

  

0.8

 median

80

80

 

 60–70

13

9

 

 80–100

32

26

 

BRAF mutation

  

0.8

 present

15

13

 

 absent

30

22

 

 undetermined

   

Extracranial disease

  

0.7

 present

34

25

 

 absent

11

10

 

Number of metastases

 

0.4

 single

8

9

 

 multiple

37

26

 

DS-GPA

  

0.3

 0–1

9

6

 

 1.5–2.5

22

16

 

 3–4

14

13

 

Type of SRS

  

0.76

 Single-fraction SRS

153

132

 

 Fractionated SRS

22

19

 

Size of metastases

  

0.8

  < 2 cm

99

84

 

 2–3 cm

46

38

 

  ≥ 3 cm

30

29

 

Total tumor volume (cm 3 )

  

0.1

 median

7.4

9.2

 

 range

0.5–33.1

0.7–33

 

GTV (cm 3 )

  

0.6

 median

1.12

1.2

 

 range

0.05–27.9

0.4–31.2

 

PTV (cm 3 )

  

0.3

 median

1.71

1.83

 

 range

0.1–39.1

0.09–42.6

 

Conformity index a

  

0.5

 median

1.43

1.41

 

 range

1.10–1.91

1.12–1.85

 
  1. SRS stereotactic radiosurgery, KPS Karnofsky Performance Status
  2. DS-GPA Diagnosis-Specific Graded Prognostic Factors, GTV Gross Target Volume
  3. PTV Planning Target Volume, acalculated as prescribed isodose volume/tumor volume
  4. encompassed by the prescription isodose volume